Research News
View articles by month and year
11–16 of 16 articles
-
Xgeva Slightly Better Than Zometa at Reducing Breast Cancer Bone Complications
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is somewhat better than Zometa at lowering the risk of bone complications in women diagnosed with breast cancer that has spread to the bones.
-
Oral Bisphosphonates May Reduce Risk for Postmenopausal Women
Two studies suggest that oral bisphosphonates may reduce the risk of invasive breast cancer in postmenopausal women by 30% to 40%.
-
Prolia Approved to Treat Osteoporosis
A new osteoporosis treatment called Prolia has been approved by the U.S. Food and Drug Administration.
-
Bisphosphonates Seem to Reduce Risk
A new study found a strong association between taking oral bisphosphonates and a lower risk of breast cancer.
-
Factors Besides Treatment Likely Contribute to Survivors’ Bone Loss
A small study shows that other factors besides breast cancer treatment contribute to bone loss in post-menopausal women.
-
Research Looks at Link Between Bone Density and Risk
Early analysis of Women's Health Initiative information suggests that post-menopausal women with strong bones are more likely to develop breast cancer.
11–16 of 16 articles
